Skip to main content
. 2022 Sep 27;13:971046. doi: 10.3389/fpsyt.2022.971046

TABLE 5.

Patient feasibility outcomes for mEMA at T1 and T2.

4 weeks post-baseline (T1)
n = 12
12 weeks post-baseline (T2)
n = 12
M (SD) Range M (SD) Range
SUS 75.83 (11.98) 60–97.5 76.25 (13.80) 60–95
CSQ-8 23.92 (2.99) 19–29 22.75 (3.36) 17–27

CSQ-8, Client Satisfaction Questionnaire-8; SUS, System Usability Scale.